Showing 4851-4860 of 6036 results for "".
- Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 3 Trial of Zimura in GA Secondary to AMDhttps://modernod.com/news/iveric-bio-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-3-trial-of-zimura-in-ga-secondary-to-amd/2479341/Iveric bio announced that the company received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to a
- CVC Capital Partners VIII to Acquire Majority Stake in Raynerhttps://modernod.com/news/cvc-capital-partners-viii-to-invest-in-rayner/2479340/CVC Capital Partners VIII announced that it has agreed to acquire a majority interest in Rayner, the global ophthalmology business from UK-based private equity firm Phoenix Equity Partners. Terms of the deal were not disclosed. The transaction is expected to close in the third quar
- Nicox to Receive $2 Million from Ocumension as Milestone Payment Under Zerviate Agreementhttps://modernod.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/Nicox announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amend
- Ocular Therapeutix and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry AMDhttps://modernod.com/news/ocular-therapeutix-and-mosaic-biosciences-enter-into-strategic-discovery-collaboration-targeting-the-treatment-of-dry-age-related-macular-degeneration/2479331/Ocular Therapeutix entered into a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents aimed at the treatment of dry age-related macular degeneration (AMD). Ocular Therapeutix has agreed to fund the research performed under the collaboration and re
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Study Finds Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adultshttps://modernod.com/news/study-finds-recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults/2479323/With the National Eye Institute reporting that about 11 million older adults in the US endure age-related macular degeneration (AMD), University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to tre
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asiahttps://modernod.com/news/panoptica-announces-licensing-agreement-with-zhaoke-ophthalmology-for-the-treatment-of-neovascular-eye-diseases-in-china-south-korea-and-southeast-asia/2479318/PanOptica announced a licensing agreement with Zhaoke Ophthalmology Limited to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy, in China, South Kor
- Gemini Therapeutics Announces Data From Ongoing Phase 2a Study in Patients with GA Secondary to Dry AMDhttps://modernod.com/news/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-patients-with-geographic-atrophy-secondary-to-dry-amd/2479317/Gemini Therapeutics announced initial data from its phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant huma
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in